TY - JOUR T1 -人类受试者的最小雾化干扰素剂量:生物后果和副作用摩根富林明——欧洲呼吸杂志乔-欧元和J SP - 42 LP - 46 - 10.1183 / 09031936.96.09010042六世- 9 - 1 AU -入内,年代盟——Casarini M盟——Ameglio F AU -阿莱曼诺L盟——Saltini C盟——Bisetti Y1 - 1996/01/01 UR - //www.qdcxjkg.com/content/9/1/42.abstract N2 -α干扰素(IFN-alpha)是一个leucocyte-derived细胞因子与多效性的影响免疫系统的细胞,包括促进病毒和微生物杀灭的能力。本研究旨在评估雾化淋巴母细胞ifn - α在正常人和慢性支气管炎患者中的生物活性剂量，使用血清2'-5'低聚腺苷酸合成酶(OAS)作为ifn - α活性的标志。研究对象分为三组:两组健康组和一组慢性支气管炎患者。对A组(对照组，n = 5)进行研究，以确定能够诱导生物效应而无副作用的最小ifn - α剂量。在剂量递增试验中给予IFN-alpha，包括0,0.3 x 10(6)， 1.0 x 10(6)和3.0 x 10(6) IU。第1天(给药5天)。只服用3.0 x 10(6) IU。ifn - α的第1天诱导了显著的生物活性，增加了血清OAS水平。B组(对照组，n = 5)和C组(慢性支气管炎，n = 5)给予3.0 × 10(6) IU。day-1 (10 day administration) in order to study serum, bronchoalveolar lavage fluid (BALF) and BALF cell modifications, after treatment. OAS serum levels and nitroblue tetrazolium (NBT) reduction tests, the latter used as a measure of phagocyte cell activity, increased both in normal subjects and in patients with chronic bronchitis. No significant change of serum IFN-alpha levels was found. It is concluded that aerosolized IFN-alpha administration to the lung is well-tolerated at biologically active doses. The activity can be monitored by quantifying OAS serum levels through a simple blood test. ER -